Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 4 of 105. Open to participants first (1,909), then studies with results posted, then the rest; newest registration first within each.
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingNCT07458919Early Phase 1
- Remibrutinib Open Label Roll-over Post-trial Access ProtocolRecruitingNCT07456891Phase 3
- Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid ArthritisNot yet recruitingNCT07452445Phase 4
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Phase 4
- Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical TrialNot yet recruitingNCT07449910Phase 2/3
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingNCT07448116Phase 1/2
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingNCT07447817Phase 2
- FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingNCT07446465Phase 4
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1
- Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.RecruitingNCT07443397Phase 3
- A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk MyelofibrosisRecruitingNCT07443306Phase 2
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
- Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADRecruitingNCT07441395Phase 2
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy VolunteersNot yet recruitingNCT07438886Phase 1
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT07436741Phase 3
- PH 2 Pemigatinib in SDH-deficient GISTRecruitingNCT07434843Phase 2
- A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2
- Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingNCT07428707Early Phase 1
- A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingNCT07428616Phase 2
- FLT3-ITD Targeted Therapy in Fit AML PatientsNot yet recruitingNCT07425808Phase 2/3
- Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)RecruitingNCT07424222Phase 1
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCNot yet recruitingNCT07418879Not applicable
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2
- Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
- Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerRecruitingNCT07415005Phase 2
- Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingNCT07414758Phase 3
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingNCT07413939Phase 2/3
- ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNot yet recruitingNCT07410611Phase 2
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Phase 3
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingNCT07407140Phase 3
- KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingNCT07406633Phase 2
- Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)Not yet recruitingNCT07406204Phase 4
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3
- A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingNCT07403968Phase 2
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingNCT07400250Phase 2
- Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
- Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingNCT07394153Phase 2
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2
- A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.RecruitingNCT07392736Phase 1/2
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingNCT07392346Phase 2
- Zanubritnib and Anti-MAG NeuropathyRecruitingNCT07392229Phase 2
- Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNot yet recruitingNCT07388875Phase 2
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT07385079Phase 3
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
- Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingNCT07382687Phase 3
- A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationNot yet recruitingNCT07381114Phase 1/2
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Phase 2/3
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07377578Phase 3
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT07376499Phase 2
- A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Phase 2
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib TabletRecruitingNCT07374224Phase 1
- Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell LymphomaRecruitingNCT07371923Phase 2
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingNCT07369739Phase 2/3
- Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2
- Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingNCT07366801Phase 2/3
- Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety StudyNot yet recruitingNCT07365410Phase 2
- Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingNCT07362836Phase 3
- A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsRecruitingNCT07361562Phase 1
- A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell TransplantRecruitingNCT07359859Phase 2
- A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or RearrangementRecruitingNCT07359820Phase 2
- A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerRecruitingNCT07358676Phase 2
- Baricitinib Effects on Procoagulant State in Rheumatoid ArthritisNot yet recruitingNCT07357649Phase 4
- Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
- Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone LymphomaRecruitingNCT07355699Phase 4
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingNCT07355010Phase 2
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
- Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)RecruitingNCT07354061Phase 1/2
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Phase 2
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
- A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
- Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisRecruitingNCT07348965Not applicable
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic RosaceaRecruitingNCT07343635Not applicable
- Dasatinib for HIV-1 Reservoir ReductionRecruitingNCT07342491Phase 1
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingNCT07341191Phase 2
- Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )RecruitingNCT07340723Phase 2
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingNCT07339345Phase 2/3
- Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsRecruitingNCT07336732Phase 2
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen SclerosusRecruitingNCT07335588Phase 3
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCCRecruitingNCT07334483Phase 2
- Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk FactorsNot yet recruitingNCT07330076Phase 2
- Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingNCT07328919Phase 3
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIRecruitingNCT07326566Phase 2
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingNCT07323641Phase 2
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingNCT07318324Phase 1
- Optimal Dose of Zanubrutinib to Treat Adult Immune ThrombocytopeniaNot yet recruitingNCT07315373Phase 1
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingNCT07315113Phase 1
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Phase 2
- Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaRecruitingNCT07314216Phase 2